Published August 2016 | Version v1
Journal article Metadata-only

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer

Creators

  • 1. University of Leeds (United Kingdom)
  • 2. Departments of Radiotherapy and Medical Physics, St James's Institute of Oncology (United Kingdom)
  • 3. Mount Vernon Cancer Centre, Northwood (United Kingdom)
  • 4. Klinik fur Strahlentherapie, Kiel (Germany)
  • 5. Institute Verbeeten, Tilburg (Netherlands)

Description

Background and purpose: To estimate the risks of radiation-induced rectal and bladder cancers following low dose rate (LDR) and high dose rate (HDR) brachytherapy as monotherapy for localised prostate cancer and compare to external beam radiotherapy techniques.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2016.05.026

Additional details

Identifiers

DOI
10.1016/j.radonc.2016.05.026;
PII
S0167814016311525;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
120
Journal Issue
2
Journal Page Range
p. 293-299
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
50080963
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BLADDER; BRACHYTHERAPY; DOSE RATES; NEOPLASMS; PROSTATE; RECTUM
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; GASTROINTESTINAL TRACT; GLANDS; INTESTINES; LARGE INTESTINE; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; THERAPY; URINARY TRACT

Optional Information

Copyright
Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.
Collaborations
on behalf of the UroGEC/BRAPHYQS group of the GEC ESTRO